[
  {
    "ts": null,
    "headline": "Jim Cramer Calls Vertex Pharmaceuticals Incorporated (VRTX) “Terrific” With “Revolutionary Pain Drug”",
    "summary": "We recently published a list of Jim Cramer Nailed These 11 Stock Picks. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other stocks that Jim Cramer discusses. On Thursday, April 3rd, the host of Mad Money opened the most recent show by addressing the growing concerns […]",
    "url": "https://finnhub.io/api/news?id=33d3ccf095458c7d3d3ab55aa5603b314c2758dcf62d3881027dd037f32a6bb8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744136691,
      "headline": "Jim Cramer Calls Vertex Pharmaceuticals Incorporated (VRTX) “Terrific” With “Revolutionary Pain Drug”",
      "id": 133795481,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "We recently published a list of Jim Cramer Nailed These 11 Stock Picks. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other stocks that Jim Cramer discusses. On Thursday, April 3rd, the host of Mad Money opened the most recent show by addressing the growing concerns […]",
      "url": "https://finnhub.io/api/news?id=33d3ccf095458c7d3d3ab55aa5603b314c2758dcf62d3881027dd037f32a6bb8"
    }
  },
  {
    "ts": null,
    "headline": "Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Long Term Growth Stock to Buy According to Billionaires?",
    "summary": "We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best long term growth stocks to buy according to billionaires. As per Barclays, the US administration announced numerous executive orders […]",
    "url": "https://finnhub.io/api/news?id=31d3fea046c06bb48cf7e60be79852c71568c7f1c65e2c859cd9287b5df30e1b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744135777,
      "headline": "Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Long Term Growth Stock to Buy According to Billionaires?",
      "id": 133795482,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best long term growth stocks to buy according to billionaires. As per Barclays, the US administration announced numerous executive orders […]",
      "url": "https://finnhub.io/api/news?id=31d3fea046c06bb48cf7e60be79852c71568c7f1c65e2c859cd9287b5df30e1b"
    }
  },
  {
    "ts": null,
    "headline": "Is Vertex Pharmaceuticals Stock a Buy?",
    "summary": "Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX).  Compared to the S&P 500 index, which is down about 16% from its record high at the time of writing, Vertex shares have outperformed, up 20% year to date.  Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is driving record sales.",
    "url": "https://finnhub.io/api/news?id=e797dbfc74d56975509414d0db53b18692da8307e98f2110c924407244a06666",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744119900,
      "headline": "Is Vertex Pharmaceuticals Stock a Buy?",
      "id": 133795483,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX).  Compared to the S&P 500 index, which is down about 16% from its record high at the time of writing, Vertex shares have outperformed, up 20% year to date.  Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is driving record sales.",
      "url": "https://finnhub.io/api/news?id=e797dbfc74d56975509414d0db53b18692da8307e98f2110c924407244a06666"
    }
  },
  {
    "ts": null,
    "headline": "VRTX Secures Nod for Expanded Use of CF Drug Kaftrio in Europe",
    "summary": "With the latest approval, Vertex's Kaftrio is now eligible to treat about 4,000 people living in the EU with rare mutations of cystic fibrosis.",
    "url": "https://finnhub.io/api/news?id=b28f45c0db2ef654cc7294b012342a01f810fe377ace79f3c3479b08343a477c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744109700,
      "headline": "VRTX Secures Nod for Expanded Use of CF Drug Kaftrio in Europe",
      "id": 133795484,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "With the latest approval, Vertex's Kaftrio is now eligible to treat about 4,000 people living in the EU with rare mutations of cystic fibrosis.",
      "url": "https://finnhub.io/api/news?id=b28f45c0db2ef654cc7294b012342a01f810fe377ace79f3c3479b08343a477c"
    }
  }
]